Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1985 Jan;48(1):65–69. doi: 10.1136/jnnp.48.1.65

Guillain-Barré syndrome following zimeldine treatment.

J Fagius, P O Osterman, A Sidén, B E Wiholm
PMCID: PMC1028185  PMID: 3156214

Abstract

Thirteen cases of the Guillain-Barré syndrome are reviewed, all occurring with a similar relationship to recent commencement of treatment with the antidepressive drug zimeldine. The risk of developing Guillain-Barré syndrome was increased about 25-fold among patients receiving zimeldine, as compared with the natural incidence of the disorder. The cases described provide strong evidence that Guillain-Barré syndrome may occur as a specific, probably immunologically mediated, complication of drug therapy.

Full text

PDF
65

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chalès G., Grosbois B., Pawlotsky Y., Louboutin J. Y., Gueguen A., Estable P. Accidents neurologiques et hépatiques de la chrysothérapie. Sem Hop. 1980 Nov 18;56(43-44):1787–1792. [PubMed] [Google Scholar]
  2. Dick D. J., Raman D. The Guillain-Barre syndrome following gold therapy. Scand J Rheumatol. 1982;11(2):119–120. doi: 10.3109/03009748209098174. [DOI] [PubMed] [Google Scholar]
  3. Dyck P. J., Lais A. C., Ohta M., Bastron J. A., Okazaki H., Groover R. V. Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc. 1975 Nov;50(11):621–637. [PubMed] [Google Scholar]
  4. Heel R. C., Morley P. A., Brogden R. N., Carmine A. A., Speight T. M., Avery G. S. Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs. 1982 Sep;24(3):169–206. doi: 10.2165/00003495-198224030-00001. [DOI] [PubMed] [Google Scholar]
  5. Hogg J. E., Kobrin D. E., Schoenberg B. S. The Guillain-Barré syndrome epidemiologic and clinical features. J Chronic Dis. 1979;32(3):227–231. doi: 10.1016/0021-9681(79)90068-7. [DOI] [PubMed] [Google Scholar]
  6. Hurwitz E. S., Holman R. C., Nelson D. B., Schonberger L. B. National surveillance for Guillain-Barré syndrome: January 1978-March 1979. Neurology. 1983 Feb;33(2):150–157. doi: 10.1212/wnl.33.2.150. [DOI] [PubMed] [Google Scholar]
  7. Katrak S. M., Pollock M., O'Brien C. P., Nukada H., Allpress S., Calder C., Palmer D. G., Grennan D. M., McCormack P. L., Laurent M. R. Clinical and morphological features of gold neuropathy. Brain. 1980 Sep;103(3):671–693. doi: 10.1093/brain/103.3.671. [DOI] [PubMed] [Google Scholar]
  8. Kennedy R. H., Danielson M. A., Mulder D. W., Kurland L. T. Guillain-Barré syndrome: a 42-year epidemiologic and clinical study. Mayo Clin Proc. 1978 Feb;53(2):93–99. [PubMed] [Google Scholar]
  9. Poser C. M. Criteria for the diagnosis of the Guillain-Barré syndrome. A critique of the NINCDS guidelines. J Neurol Sci. 1981 Nov-Dec;52(2-3):191–199. doi: 10.1016/0022-510x(81)90004-6. [DOI] [PubMed] [Google Scholar]
  10. Schonberger L. B., Bregman D. J., Sullivan-Bolyai J. Z., Keenlyside R. A., Ziegler D. W., Retailliau H. F., Eddins D. L., Bryan J. A. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976--1977. Am J Epidemiol. 1979 Aug;110(2):105–123. doi: 10.1093/oxfordjournals.aje.a112795. [DOI] [PubMed] [Google Scholar]
  11. Schonberger L. B., Hurwitz E. S., Katona P., Holman R. C., Bregman D. J. Guillain-Barré syndrome: its epidemiology and associations with influenza vaccination. Ann Neurol. 1981;9 (Suppl):31–38. doi: 10.1002/ana.410090707. [DOI] [PubMed] [Google Scholar]
  12. Walsh J. C. Gold neuropathy. Neurology. 1970 May;20(5):455–458. doi: 10.1212/wnl.20.5.455. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES